Genotoxic impurities: A regulatory toxicology commentary on recent articles in organic process research & development

Organic Process Research and Development

Volumn 15, Issue 6, 2011, Pages 1243-1246

  Snodin, David J ^a  

^a Xiphora Biopharma Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EU GUIDELINES; GENOTOXIC IMPURITIES; PUBLIC DOMAINS; REGULATORY GUIDANCE; TOXICOLOGICAL ANALYSIS;

IMPURITIES;

EID: 81555200718     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op200205b     Document Type: Article

References (20)

1. Kasper, P. Genotoxic Impurities and Risk - Managing the Unknown: http://www.gta-us.org/2009MeetingDocuments/Invited%20Speakers%20Presentations/ Kasper.pdf.
2. Snyder, R. D. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity Environ. Mol. Mutagen 2009, 50 (6) 435-50
3. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food (AFC). Flavouring Group Evaluation 52 (FGE.52). EFSA J. 2008, 637, 1-69: http://www.efsa.europa.eu/fr/ scdocs/doc/637.pdf.
4. Kirkland, D.; Aardema, M.; Henderson, L.; Müller, L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 2005, 584 (1-2) 1-256 (Pubitemid 40922793)
5. European Commission. Risk assessment methodologies and approaches for genotoxic and carcinogenic substances; 2009,: http://ec.europa.eu/health/ph- risk/committees/04-scher/docs/scher-o-113.pdf.
6. Giordani, A.; Kobel, W.; Gally, H. U. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process Eur. J. Pharm. Sci. 2011, 43 (1-2) 1-15
7. Elder, D. P.; Harvey, J. S. Is there a real case for cumulative control of structurally related impurities? Org. Process Res. Dev. 2010, 14, 1037-1045
8. Raillard, S. P.; Bercu, J; Baertschi, S. W.; Riley, C. M. Prediction of Drug Degradation Pathways leading to Structural Alerts for Potential Genotoxic Impurities Org. Process Res. Dev. 2010, 14, 1015-1020
9. Sun, M; Liu, D. Q.; Kord, A. S. A Systematic Method Development Strategy for Determination of Pharmaceutical Genotoxic Impurities Org. Process Res. Dev. 2010, 14, 977-985
10. Callis, C. M.; Bercu, J. P.; DeVries, K. M.; Dow, L. K.; Robbins, D. K.; Varie, D. L. Risk Assessment of Genotoxic Impurities in Marketed Compounds Administered over a Short-Term Duration. Applications to Oncology Products and Implications for Impurity Control Limits Org. Process Res. Dev. 2010, 14, 986-992
11. Vogel, E. W.; Nivard, M. J. International Commission for Protection Against Environmental Mutagens and Carcinogens. The subtlety of alkylating agents in reactions with biological macromolecules Mutat. Res. 1994, 305 (1) 13-32
12. Raman, N. V.; Prasad, A. V.; Ratnakar Reddy, K. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective J. Pharm. Biomed. Anal. 2011, 55 (4) 662-7
13. Schülé, A.; Ates, C.; Palacio, M.; Stofferis, J.; Delatinne, J.-P.; Martin, B.; Lloyd, S. Monitoring and Control of Genotoxic Impurity Acetamide in the Synthesis of Zaurategrast Sulfate Org. Process Res. Dev. 2010, 14, 1008-1014
14. Robinson, D. I. Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective Org. Process Res. Dev. 2010, 14, 946-959
15. Adler, I. D.; Tinwell, H.; Kliesch, U.; Ashby, J. Activity of iPMS and nPMS in mouse bone marrow micronucleus assays: comparison with mouse dominant lethal assay data Mutat. Res. 1996, 349 (2) 241-7 (Pubitemid 26060870)
16. Bercu, J. P.; Morton, S. M.; Deahl, J. T.; Gombar, V. K.; Callis, C. M.; van Lier, R. B. In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances Regul. Toxicol. Pharmacol. 2010, 57 (2-3) 300-6
17. Contrera, J. F. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities Regul. Toxicol. Pharmacol. 2011, 59 (1) 133-41
18. Serafimova, R.; Gatnik, M. F.; Worth, A. Review of QSAR models and software tools for predicting genotoxicity and carcinogenicity. JRC Scientific and Technical Report EUR 24427 EN-2010: http://publications.jrc.ec.europa.eu/ repository/bitstream/111111111/14330/1/jrc%20report-genotoxicity%20qsar.pdf.
19. Kroes, R.; Renwick, A. G.; Cheeseman, M.; Kleiner, J.; Mangelsdorf, I.; Piersma, A.; Schilter, B.; Schlatter, J.; van Schothorst, F.; Vos, J. G.; Würtzen, G. European branch of the International Life Sciences Institute. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet Food Chem. Toxicol. 2004, 42 (1) 65-83 (Pubitemid 37421327)
20. Cheeseman, M. A.; Machuga, E. J.; Bailey, A. B. A tiered approach to threshold of regulation Food Chem. Toxicol. 1999, 37 (4) 387-412 (Pubitemid 29335764)